Antifibrotic agents, like Imatinib, a Bcr‐Abl inhibitor and a blocker of various tyrosine kinases, is currently under evaluation in individuals with liver fibrosis, despite its previous failure in treating idiopathic pulmonary fibrosis (IPF). The gene discussed is ABL1; the disease is idiopathic pulmonary fibrosis.